Patents
Literature
8 results about "Neutral lipid" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
Neutral lipid storage disease with myopathy is a condition in which fats (lipids) are stored abnormally in organs and tissues throughout the body. People with this condition have muscle weakness (myopathy) due to the accumulation of fats in muscle tissue.
Ionisable lipids
Owner:COMMONWEALTH SCI & IND RES ORG
Lipid compound and lipid nanoparticle composition
The present disclosure provides a lipid compound, which can be used in combination with other lipid components, such as neutral lipids, cholesterol, and polymer-lipid conjugates, to form lipid nanoparticles for delivery of therapeutic agents (e.g. nucleic acid molecules) for therapeutic or prophylactic purposes, comprising vaccination. Also provided herein is a lipid nanoparticle composition comprising the lipid compound.
Owner:CNBG-VIROGIN BIOTECH (SHANGHAI) CO LTD +1
Lipid Nanoparticle Formulations for Anti-Sense Oligonucleotide Delivery
Provided herein is a lipid nanoparticle comprising an encapsulated oligonucleotide molecule, wherein the oligonucleotide molecule is single-stranded or double-stranded and has a length of between 5 and 500 nucleotides; and 20 to 70 mol % of a neutral lipid content relative to total lipid present in the lipid nanoparticle, an ionizable lipid; a sterol; and optionally a hydrophilic polymer-lipid conjugate.
Owner:NANOVATION THERAPEUTICS INC
Methods for delivering DNA or RNA cargo using unshielded lipid nanoparticles
This disclosure provides unshielded lipid nanoparticles and a method for producing such unshielded lipid nanoparticles, thereby overcoming the challenge of preparing particles without causing their aggregation. The lipid nanoparticles comprise nucleic acid cargo molecules; sterols or derivatives thereof present in an amount of at least 12% molar ratio; neutral lipids, such as phospholipids having a choline head group, in an amount of 22% to 65% molar ratio; and ionizable cationic amino lipids in an amount of 15% to 45% molar ratio; wherein the lipid nanoparticles are not sterically stabilized by a hydrophilic polymer-lipid conjugate or are unshielded, and wherein each % molar ratio is relative to the total lipids present in the lipid nanoparticles.
Owner:NANOVATION THERAPEUTICS INC
Lipid nanoparticles having non-polar lipids for extrahepatic nucleic acid delivery
PCT designated stageWO2026107609A1Organic active ingredientsGenetic therapy composition manufactureSterolNanoparticle
The present disclosure provides a lipid nanoparticle comprising: nucleic acid cargo; ionizable lipid; non-polar, neutral lipid, such as a phospholipid; non-polar lipid, such as a glyceride; and sterol, the lipid nanoparticle being unshielded and wherein each mol% content is relative to total lipid present in the lipid nanoparticle.
Owner:NANOVATION THERAPEUTICS INC
Polyglycerol conjugated lipid compounds and lipid nanoparticle compositions
Provided herein are polyglycerol conjugated lipid compounds that can be used in combination with other lipid components, such as cationic lipids, neutral lipids, and cholesterol, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nucleic acid molecules) for therapeutic or prophylactic purposes. Also provided herein are lipid nanoparticle compositions comprising said polymer conjugated lipid compounds.
Owner:SUZHOU ABOGEN BIOSCIENCES CO LTD
Liposomal pemetrexed and methods of making and using the same
PendingCN122140625AOrganic active ingredientsPharmaceutical delivery mechanismSide effectCholesterol
The application discloses a kind of pemetrexed liposome and its preparation method and application, it is made of including 2mg / mL~20mg / mL pemetrexed or its pharmaceutically acceptable salt, 2.2mg / mL~12mg / mL cholesterols, 6.81mg / mL~108mg / mL neutral lipid, 12mg / mL~98mg / mL cationic lipid and 0.12mg / mL~2.12mg / mL PEG-lipid.The pemetrexed liposome of the application can significantly improve the enrichment of pemetrexed drug in tumor site, thereby enhancing drug treatment effect, reducing dosing dose, reducing the toxic side effects of drug on normal tissue.And it has good stability, no obvious change in storage process nature, particle size, zeta potential and encapsulation efficiency.
Owner:SHENZHEN NYCRIST TECH CO LTD
Aminolipids, lipid nanoparticles and their use
PendingJP2026516582AOrganic active ingredientsCarboxylic acid nitrile preparationIntracellularNanoparticle
This invention provides aminolipids, lipid nanoparticles, and their uses. The aminolipids have a structure represented by general formula (I), or isomers thereof, pharmaceutically acceptable salts, prodrugs, or solvates. This invention further provides lipid nanoparticles containing these aminolipids. In this invention, an aminolipid having the structure represented by general formula (I) is used as an ionizable lipid compound and obtained LNP by self-assembling with a steroid, a neutral lipid, and a polymer-bound lipid. These LNPs improve the intracellular translational expression level of the supported nucleic acid, enhance the action of nucleic acid-LNP formulations, and provide a theoretical basis for personalized therapy with nucleic acid-LNP formulations. TIFF2026516582000075.tif28170
Owner:深せんHONGXIN BIOTECHNOLOGY CO LTD